ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL
- Status
- RECRUITING
- Phase
- PHASE3
Clinical Trials Related to SLL
Related studies linked through entity extraction aliases.
Anti CD19 CAR-T Combined With BTKi to Treat Newly Diagnosed High-risk CLL/SLL
- Status
- RECRUITING
- Phase
- NA
Study of Epcoritamab as a Consolidation Therapy in CLL/SLL
- Status
- RECRUITING
- Phase
- PHASE2
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
- Status
- RECRUITING
- Phase
- PHASE3
Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia
- Status
- TERMINATED
- Phase
- PHASE1
CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia
- Status
- RECRUITING
- Phase
- PHASE1
A Time-Limited Approach to Treatment With Ibrutinib for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
- Status
- WITHDRAWN
- Phase
- N/A
Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL/SLL
- Status
- WITHDRAWN
- Phase
- PHASE1
Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Registry of the German CLL Study Group
- Status
- RECRUITING
- Phase
- N/A
Safety, Tolerability and Efficacy of A6 in Patients With Chronic Lymphocytic Leukemia (CLL)
- Status
- TERMINATED
- Phase
- PHASE2
Ofatumumab With High Dose Methylprednisone Followed by Ofatumumab and Alemtuzumab in 17p CLL
- Status
- TERMINATED
- Phase
- PHASE2
Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2